Drug Trial Radar · NCT05262400
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
235
Actual
Start
Mar 14, 2022
Primary completion
Feb 26, 2027
Study completion Feb 26, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount of study medicines that can be safety given to people. All participants in this study will receive PF-07220060 with PF-07104091 by mouth. We will compare participant experiences to help us determine if PF-07220060 with PF-07104091 is safe and effective. Participants will take part in this study for about 2 years. During this time, they will receive the study medicine, an x-ray imaging, and will be observed for safety and effects of the study medicines.
Conditions
- Breast Cancer
- Solid Tumors
Interventions
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07104091 + PF-07220060 + fulvestrant dose expansionDrug
PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
PF-07104091 + PF-07220060 + fulvestrant dose expansionDrug
PF-07104091 and PF-07220060 will be administered orally in combination with fulvestrant
PF-07104091 + PF-07220060 + letrozole dose expansionDrug
PF-07104091 and PF-07220060 will be administered orally in combination with letrozole
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
PF-07220060 + PF-07104091 combination dose escalationDrug
PF-07104091 and PF-07220060 will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of participants with Dose-limiting toxicities (DLT) during first cycleTime frame: Cycle 1 (28 days)
- Number of participants with treatment emergent adverse events (AEs)Time frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Incidence of participants with clinical laboratory abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Number of participants with vital signs abnormalitiesTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
- Number of participants with corrected QT (QTc) intervalTime frame: From baseline until end of study treatment or study completion (approximately 2 years)
Locations
44 sites in 9 countries. Site status is shown where the registry gives one.
Administrative Address: UCLA Hematology/Oncology
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
UCLA Hematology / Oncology-Parkside
Santa Monica, California
UCLA Hematology/Oncology-Santa Monica
Santa Monica, California
Massachusetts General Hospital
Boston, Massachusetts
START Midwest
Grand Rapids, Michigan
Saint Luke's Cancer Institute
Kansas City, Missouri
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Swedish Medical Center
Seattle, Washington
Swedish Medical Center
Seattle, Washington
Centro Oncologico Korben
Buenos Aires, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, Argentina
Fundación CORI para la Investigación y Prevención del Cáncer
La Rioja, Argentina
Clinica Viedma S. A
Viedma, Río Negro Province, Argentina
Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda
São Paulo, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Ijuí, Rio Grande do Sul, Brazil
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
Porto Alegre, Rio Grande do Sul, Brazil
Centro de Pesquisa Clínica - Área Administrativa
Porto Alegre, Rio Grande do Sul, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, São Paulo, Brazil
Specialized Hospital for Active Treatment of Oncology - Haskovo
Haskovo, Bulgaria
Complex Oncology Center - Plovdiv EOOD
Plovdiv, Bulgaria
Complex Oncology Center - Vratsa
Vratsa, Bulgaria
Multiprofile Hospital for Active Treatment Serdikamed EOOD
Sofia, Sofia (stolitsa), Bulgaria
The First Hospital of Jilin University
Changchun, Jilin, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Vseobecna fakultni nemocnice v Praze
Prague, Czechia
Všeobecná fakultní nemocnice v Praze
Prague, Czechia
Fakultni nemocnice Olomouc
Olomouc, Olomouc Region, Czechia
Fakultni nemocnice Bulovka
Prague, Praha 8, Czechia
Instituto Nacional de Cancerologia
Mexico City, Mexico City, Mexico
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monterrey, Nuevo León, Mexico
Mérida Investigación Clínica
Mérida, Yucatán, Mexico
FARMOVS
Bloemfontein, Free State, South Africa
Wits Clinical Research
Johannesburg, Gauteng, South Africa
Hospital Universitario Virgen Del Rocio
Seville, Spain
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.